90 likes | 208 Views
RVIPP Regional Meeting June 23-26, 2009 Indiana State Report. Dawne DiOrio Rekas, M.P.A. Assistant STD Program Manager IPP Coordinator. Topics to update. EPT progress Pregnancy-test only visit testing at Title X clinics Partner notification and treatment for IPP clinics
E N D
RVIPP Regional MeetingJune 23-26, 2009Indiana State Report Dawne DiOrio Rekas, M.P.A. Assistant STD Program Manager IPP Coordinator
Topics to update • EPT progress • Pregnancy-test only visit testing at Title X clinics • Partner notification and treatment for IPP clinics • Data problems uncovered • 2008 Prevention Effectiveness • HEDIS measure/Whose data is it?
EPT • Presented our request to Medical Licensing Board on March 26 • Regulation change requested prohibiting physician from prescribing or dispensing unless he has personally examined patient • MLB/OPLA; ISMA; Trial Lawyers Ass’n; State AG; ISDH attorney • Still no decision
PTO Chlamydia screening • 4th quarter problems with implementation • 4th quarter 282 screened, 8% CT and 1% GC positivity • 1st Q 2009 – some improvement • 326 screened, 9% CT and 2% GC positivity • Only 7 clinics (of 29 eligible) sent specimens • Range of submissions per clinic: 5 to 147 • IFHC sent another directive to conduct testing
Partner treatment • Form used by some (not all) clinics for partner info udpated and distributed to all IPP clinics and DIS statewide • Outcome of notification by DIS and treatment of partners reflected by STD*MIS data
Data Problems • Three source files: ISDH Lab, Marion Co. Health Dept. Lab, and Center for Disease Detection (via Planned Parenthood) • 2008 not all files received or submitted to RVIPP • Data for provider type, selective screening site, etc. not accurate • Much appreciation to Charlie, Steve, and Shana for help
Prevention effectiveness • CDC economic analysis tool – STICFigure Automatically calculates STD Program cost effectiveness as a result of program disease intervention (treatment of patients, partners, and case management) • Includes early syphilis, HIV, gonorrhea, and chlamydia • In 2008, Indiana’s STD Program saved $6.2M in medical costs (direct and indirect) • $2.60 saved for every $1 spent
Indiana’s hedis measure Region V
Whose data is it? • Managed care organizations requested access to CT screening data through ISDH Lab records and district STD sites • They proposed to send their patient list for us to match to verify if that patient had a CT test • Differing interpretations between local (STD district office) legal counsel and state counsel; HIPAA concerns; CDC involvement • Differing viewpoints on “fairness” of increasing HEDIS measure through IPP